Dissemin is shutting down on January 1st, 2025

Published in

Massachusetts Medical Society, New England Journal of Medicine, 23(373), p. 2247-2257

DOI: 10.1056/nejmoa1509225

Massachusetts Medical Society, New England Journal of Medicine, 23(373), p. 2247-2257

DOI: 10.1056/nejmoa1509255

Links

Tools

Export citation

Search in Google Scholar

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Journal article published in 2015 by Marc A. Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C. Gerstein, Lars V. Køber, Francesca C. Lawson, Lin Ping, Xiaodan Wei, Eldrin F. Lewis, Aldo P. Maggioni ORCID, John J. V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Scott D. Solomon and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event.